Capricor Therapeutics (CAPR) Faces Securities Fraud Class Action Lawsuit
A securities fraud class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for investors who purchased its securities between December 17, 2025, and July 26, 2026.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing a class action lawsuit alleging securities fraud. The lawsuit targets investors who purchased the company's securities during the period from December 17, 2025, through July 26, 2026.
Allegations in the lawsuit suggest that investors may have experienced substantial losses due to a decline in the value of their holdings. The class action aims to consolidate claims from affected investors and potentially appoint a lead plaintiff to guide the legal proceedings.
A deadline for interested parties to seek appointment as lead plaintiff is approaching. Investors who believe they have incurred losses and meet the criteria are advised to contact legal counsel to learn more about their potential involvement.
Capricor Therapeutics is a biotechnology company focused on developing treatments for serious diseases. The outcome of this litigation could have significant implications for the company's reputation and financial standing.